Cargando…

Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study

AIM: To identify factors associated with documented symptomatic and severe hypoglycaemia over 4 years in people with type 2 diabetes starting insulin therapy. MATERIALS AND METHODS: CREDIT, a prospective international observational study, collected data over 4 years on people starting any insulin in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Home, Philip, Calvi‐Gries, Francoise, Blonde, Lawrence, Pilorget, Valerie, Berlingieri, Joseph, Freemantle, Nick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887914/ https://www.ncbi.nlm.nih.gov/pubmed/29205734 http://dx.doi.org/10.1111/dom.13179

Ejemplares similares

Relationship of glycaemic control and hypoglycaemic episodes to 4‐year cardiovascular outcomes in people with type 2 diabetes starting insulin
por: Freemantle, N., et al.
Publicado: (2015)

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes
por: Home, P D, et al.
Publicado: (2015)

A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes
por: Freemantle, N, et al.
Publicado: (2013)

Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme
por: Blonde, Lawrence, et al.
Publicado: (2021)

Insulin Hypoglycæmia
Publicado: (1948)

Hypoglycaemia is reduced with use of inhaled Technosphere(®) Insulin relative to insulin aspart in type 1 diabetes mellitus
por: Seaquist, E. R., et al.
Publicado: (2019)

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
por: McCrimmon, Rory J., et al.
Publicado: (2022)

A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study
por: Gordon, J, et al.
Publicado: (2010)

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial
por: Bolli, Geremia B., et al.
Publicado: (2020)

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)
por: Home, Philip D., et al.
Publicado: (2017)

Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes
por: Freemantle, N, et al.
Publicado: (2012)

Approach to assessing the economic impact of insulin‐related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool
por: Parekh, W. A., et al.
Publicado: (2015)

The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM
por: Renard, Eric, et al.
Publicado: (2021)

A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia
por: Heller, S., et al.
Publicado: (2015)

Evaluation of Hypoglycaemia with Non-Invasive Sensors in People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia
por: Elvebakk, Ole, et al.
Publicado: (2018)

Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials
por: Freemantle, N, et al.
Publicado: (2013)

Insulin Therapy and Cancer
por: Home, Philip
Publicado: (2013)

A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design
por: Kristensen, Peter Lommer, et al.
Publicado: (2012)

Credit Where Credit is Due
Publicado: (2009)

Credit to Whom Credit Is Due
Publicado: (1871)

Credit to Whom Credit Is Due
Publicado: (1853)

Credit to Whom Credit Is Due
Publicado: (1855)

Credit to Whom Credit Is Due
Publicado: (1888)

Credit to Whom Credit Is Due
Publicado: (1883)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

Assessing the impact of a new delivery method of insulin on glycemic control using a novel trial design
por: Strack, Thomas, et al.
Publicado: (2009)

Limited impact of impaired awareness of hypoglycaemia and severe hypoglycaemia on the inflammatory profile of people with type 1 diabetes
por: Ali, Namam, et al.
Publicado: (2020)

Clinical outcomes in high‐hypoglycaemia‐risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first‐generation basal insulin analogue in the United States : Results from the DELIVER High Risk real‐world study
por: Sullivan, Sean D., et al.
Publicado: (2021)

Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs
por: Signorovitch, J E, et al.
Publicado: (2013)

Does hypoglycaemia affect the improvement in QoL after the transition to insulin in people with type 2 diabetes?
por: Wieringa, T. H., et al.
Publicado: (2017)

Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real‐world results from the DELIVER Naïve cohort study
por: Bailey, Timothy S., et al.
Publicado: (2019)

Successful Treatment with Bedtime Basal Insulin Added to Metformin without Weight Gain or Hypoglycaemia over Three Years
por: Mertes, Bernardo, et al.
Publicado: (2020)

Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia
por: Reviriego, J, et al.
Publicado: (2008)

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study
por: Galstyan, Gagik R., et al.
Publicado: (2022)

Hypoglycæmia
Publicado: (1934)

A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes1
por: Home, P D, et al.
Publicado: (2007)

Homebuying tips on credit and credit scores
por: Warren, Carolyn, et al.
Publicado: (2010)

Author Correction: Evaluation of Hypoglycaemia with Non-Invasive Sensors in People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia
por: Elvebakk, Ole, et al.
Publicado: (2019)

Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
por: Home, Philip, et al.
Publicado: (2018)

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension
por: Riddle, M C, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_31edsr8usl8hq89u6n71av0fgh